Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Eva Martinez-Balibrea"'
Autor:
Eva Martinez-Balibrea, Yari Ciribilli
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Externí odkaz:
https://doaj.org/article/fa701cf929c34a40ab57044053621213
Autor:
Vicenç Ruiz de Porras, Sara Bystrup, Sara Cabrero-de las Heras, Eva Musulén, Luis Palomero, Maria Henar Alonso, Rocio Nieto, Diego Arango, Víctor Moreno, Cristina Queralt, José Luis Manzano, Laura Layos, Cristina Bugés, Eva Martinez-Balibrea
Publikováno v:
Cancers, Vol 11, Iss 10, p 1540 (2019)
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pat
Externí odkaz:
https://doaj.org/article/2b11169517424677a0f37a52b1a8612a
Autor:
Paula Lopez-Serra, Miguel Marcilla, Alberto Villanueva, Antonio Ramos-Fernandez, Anna Palau, Lucía Leal, Jessica E. Wahi, Fernando Setien-Baranda, Karolina Szczesna, Catia Moutinho, Anna Martinez-Cardus, Holger Heyn, Juan Sandoval, Sara Puertas, August Vidal, Xavier Sanjuan, Eva Martinez-Balibrea, Francesc Viñals, Jose C. Perales, Jesper B. Bramsem, Torben F. Ørntoft, Claus L. Andersen, Josep Tabernero, Ultan McDermott, Matthew B. Boxer, Matthew G. Vander Heiden, Juan Pablo Albar, Manel Esteller
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-2 (2016)
Nature Communications 5: Article number: 4608 (2014); Published: 3 April 2014; Updated: 2 November 2016 During the preparation of the PCR gel panels in Fig. 1b,c, duplicate or otherwise irrelevant lanes were excised; these excisions were not noted in
Externí odkaz:
https://doaj.org/article/1212820cdf384abb99b859bb04a5fec8
Publikováno v:
Seminars in Cancer Biology. 73:321-330
Colorectal cancer (CRC) is the second cause of cancer death worldwide. The metastatic disease is mainly treated with aggressive therapies consisting on combinations of cytotoxic chemotherapy plus anti-EGFR or anti-VEGF drugs. In spite of the improvem
Autor:
Sara Cabrero-de las Heras, Xavier Hernández-Yagüe, Andrea González, Ferran Losa, Gemma Soler, Cristina Bugés, Iosune Baraibar, Anna Esteve, Miguel Ángel Pardo-Cea, Anne Hansen Ree, Neus Martínez-Bosch, Maria Nieva, Eva Musulén, Sebastian Meltzer, Tania Lobato, Carla Vendrell-Ayats, Cristina Queralt, Pilar Navarro, Clara Montagut, Ferran Grau-Leal, David Camacho, Raquel Legido, Núria Mulet-Margalef, Eva Martínez-Balibrea
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 176, Iss , Pp 116857- (2024)
Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-l
Externí odkaz:
https://doaj.org/article/9a44f4acd0ee417b9239aafcd72443e1
Autor:
Albert Font, David Olmos, Martin Bakht, Sara Bystrup, José Francisco Suárez, Alberto Indacochea, Carme Sole-Blanch, Eva Martinez-Balibrea, Luis Palomero, Alvaro Aytes, Natalia Jiménez, Himisha Beltran, Mercedes Marín-Aguilera, Elena Castro, Vicenç Ruiz de Porras, Josep M. Piulats, Oscar Buisan, Juan Carlos Pardo, Begoña Mellado, Xieng C. Wang, Vincenza Conteduca
Publikováno v:
Università degli studi di Foggia-IRIS
European Urology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de la UB
Universidad de Barcelona
European Urology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Background: Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::351476a91e1a705af71b18427a335885
http://hdl.handle.net/2445/178257
http://hdl.handle.net/2445/178257
Publikováno v:
World Journal of Gastroenterology
Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women, worldwide. In the early stages of the disease, biomarkers predicting early relapse would improve survival rates. In metastatic patients, the us
Autor:
Eva Martinez-Balibrea, José Francisco Suárez, Carme Sole-Blanch, Luis Palomero, Albert Font, Juan Carlos Pardo, Xieng C. Wang, Begoña Mellado, Natalia Jiménez, Alvaro Aytes, Mercedes Marín-Aguilera, Josep M. Piulats, Sara Bystrup, Vicenç Ruiz de Porras, Alberto Indacochea
BackgroundTaxanes are the most active chemotherapy agents in metastatic castration resistant prostate cancer (mCRPC) patients, yet resistance almost invariably occurs representing an important clinical challenge. Taxane-platinum combinations have sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7613e361eb32a1eb6eca01df9cd066f4
https://doi.org/10.1101/2020.01.20.912824
https://doi.org/10.1101/2020.01.20.912824
Autor:
Cristina Moreta-Moraleda, Cristina Queralt, Carla Vendrell-Ayats, Sonia Forcales, Eva Martínez-Balibrea
Publikováno v:
Pharmacological Research, Vol 196, Iss , Pp 106924- (2023)
Colorectal cancer (CRC) ranks as the third most prevalent cancer globally and stands as the fourth leading cause of cancer-related fatalities in 2020. Survival rates for metastatic disease have slightly improved in recent decades, with clinical trial
Externí odkaz:
https://doaj.org/article/18443d7e6844490da256d8a2aed2dbb6
Autor:
F. Laguía, A. Font, Natalia Jiménez, Eva Martinez-Balibrea, Jose Luis Ramirez, Begoña Mellado, V. Ruiz de Porras, Mercedes Marín-Aguilera
Publikováno v:
Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background PI3K/AKT/mTOR and MEK/ERK signalling pathways act cooperatively to develop taxane resistance in metastatic castration resistant prostate cancer (mCRPC). Inhibition of one of the pathways promotes a negative feedback that activates the othe